Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
NF-κB Inhibitor
Amorfrutin A is an NF-κB inhibitor that inhibits TNF-α-induced IκBα degradation, p65 nuclear translocation, and DNA-binding activity of the NF-κB complex. This compound promotes apoptosis in HeLa cells by enhancing the proteolytic activities of caspase-3 and PARP. Its mechanism suggests potential research applications in studying inflammation, cancer biology, and cell death pathways. -
IRAK4 Inhibitor
Emavusertib tosylate is a potent inhibitor of IRAK4, displaying an IC50 of 57 nM. By targeting IRAK4 and FLT3, it effectively disrupts NF-κB and MyD88 signaling pathways, resulting in the reduction of pro-inflammatory cytokines such as IL-6 and IL-10. This compound demonstrates significant anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptotic mechanisms. Additionally, Emavusertib tosylate has shown noteworthy antitumor activity in preclinical mouse models, making it a valuable reagent for cancer research and inflammation studies. -
TAK1 Inhibitor
Triptriolide is a TAK1 inhibitor that plays a pivotal role in regulating apoptosis in mouse podocytes. It enhances cell survival and protects podocyte function by modulating the Bcl-2 family proteins and inhibiting Caspase-3 activity. Additionally, Triptriolide activates the TAK1-NF-κB signaling pathway, leading to the upregulation of podocin. This reagent is relevant for studies focusing on kidney health and podocyte resilience under stress conditions. -
IRAK4 Inhibitor
Emavusertib mesylate is a potent inhibitor of IRAK4, demonstrating an IC50 of 57 nM. This orally active compound effectively disrupts the NF-κB and MyD88 signaling pathways, leading to a reduction in pro-inflammatory cytokines such as IL-6 and IL-10. Emavusertib mesylate displays anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptosis. Additionally, it has shown significant antitumor activity in mouse models, making it valuable for cancer research and therapeutic studies targeting inflammatory pathways. -
NF-κB/MAPK/FAK/Akt Inhibitor
Ephemeranthol A is an inhibitor of NF-κB, MAPK, FAK, and Akt signaling pathways. This phenanthrene compound demonstrates notable anti-inflammatory effects through the inhibition of NF-κB and MAPK pathways in macrophages. Additionally, Ephemeranthol A induces apoptosis and inhibits metastasis in non-small cell lung cancer by suppressing FAK/Akt signaling and epithelial-mesenchymal transition (EMT) processes. It is applicable for research into acute and chronic inflammatory diseases as well as non-small cell lung cancer. -
NF-κB p65 Inhibitor, Apoptosis Inducer
N-Desmethyldauricine is an inhibitor of NF-κB p65 with significant apoptotic effects. It effectively reduces p65 protein expression, induces apoptosis, and arrests the cell cycle at the G0/G1 phase. Additionally, N-Desmethyldauricine attenuates intercellular adhesion and inhibits the growth of 3D spheroids derived from triple-negative breast cancer. This compound is useful for research involving triple-negative breast cancer dynamics and therapeutic strategies. -
NF-κB Inhibitor
15-Deoxy-Δ12,14-prostaglandin A1 is a potent inhibitor of NF-κB signaling, functioning through the modulation of inflammatory pathways. It has been shown to induce apoptosis and effectively inhibit TNF-α-induced upregulation of adhesion molecules on endothelial cells, thereby preventing monocyte arrest. This compound is valuable for research in inflammation, cardiovascular diseases, and apoptosis studies. -
NF-κB Inhibitor
Declopramide is a potent NF-κB inhibitor that exerts antitumor effects by inducing apoptosis in cancer cells. It has demonstrated efficacy in inhibiting the proliferation of HL60 and K562 cell lines, as well as reducing tumor growth in a mouse model of human brain astrocytoma (T24). Additionally, Declopramide functions as a chemosensitizer, making it a valuable tool for investigating therapeutic strategies in cancer research. -
TLR4/NF-κB Inhibitor
TLR4/NF-κB-IN-1 is a selective inhibitor of the TLR4/NF-κB signaling pathway, demonstrating significant anti-inflammatory properties. This compound exhibits the ability to penetrate the blood-brain barrier, making it suitable for studies involving neuroinflammation. In murine models, TLR4/NF-κB-IN-1 effectively reduces acute neuroinflammation induced by lipopolysaccharides (LPS) while downregulating the expression of TLR4, phosphorylated NF-κB, and phosphorylated IκB-α proteins, providing a valuable tool for researching neuroinflammatory processes and their therapeutic modulation. -
TLR4/MyD88/NF-κB Inhibitor
SjDX5-271 is a small peptide inhibitor targeting the TLR4/MyD88/NF-κB signaling pathway. It is known to induce cell polarization and mitigate hepatic inflammation, demonstrating protective effects against liver ischemia-reperfusion injury in mouse models. This compound is valuable for research in immunology and liver-related inflammation studies. -
TLR7/TLR9 Inhibitor
ODN 24888 is a guanine-modified inhibitory oligonucleotide (INH-ODN) that specifically targets TLR7 and TLR9 signaling pathways. It effectively inhibits interferon-alpha (IFN-α) secretion and NF-κB activation, while also reducing interleukin-6 (IL-6) release. ODN 24888 is valuable for studying immune and inflammatory responses and can be utilized as a vaccine adjuvant in various research applications. -
TLR Inhibitor
TIC10g is a dual inhibitor of toll-like receptors 7 and 9 (TLR7 and TLR9). It effectively decreases TNF-α release in mouse macrophages and human B lymphocytes, with IC50 values of 14.5 μM and 6.5 μM for TLR7, and 7.69 μM and 11.5 μM for TLR9, respectively. TIC10g also inhibits the activation of NF-κB and MAPK pathways, demonstrating potential as an anti-inflammatory agent in conditions such as systemic lupus erythematosus and rheumatoid arthritis. -
TLR4 Signaling Inhibitor
NCI126224 is a TLR4 signaling inhibitor that modulates immune responses by suppressing lipopolysaccharide (LPS)-induced production of key inflammatory mediators, including NF-κB, TNF-α, IL-1β, and nitric oxide. This compound demonstrates biological activity in the low nanomolar to low micromolar range, making it a valuable tool for research into inflammatory diseases and their mechanisms. Its ability to interfere with TLR4 signaling pathways positions NCI126224 as a significant reagent for exploring potential therapeutic strategies in inflammation-related studies. -
TLR4/NF-kB/MAPK Inhibitor
TLR4/NF-κB/MAPK-IN-1 is an inhibitor targeting the TLR4/NF-κB/MAPK signaling pathways. It exhibits significant anti-neuroinflammatory activity by suppressing the activation of these pathways, leading to reduced inflammatory responses. This compound is particularly useful for research applications focusing on neuroinflammation and related neurodegenerative diseases. -
TLR4/NF-κB Inhibitor
Ligusticum cycloprolactam is a potent TLR4/NF-κB inhibitor with significant anti-inflammatory properties. It has been shown to alleviate renal injury by effectively disrupting the TLR4/NF-κB signaling pathway in both in vivo and in vitro models. In studies, Ligusticum cycloprolactam reduces serum uric acid levels, diminishes tubular damage, and decreases inflammatory infiltration and interstitial collagen deposition, leading to improved renal function. This compound serves as a valuable reagent for research into hyperuricemic nephropathy. -
NF-κB Inhibitor
NF-κB-IN-14 is an NF-κB inhibitor that effectively modulates inflammatory responses by significantly inhibiting nitric oxide production in LPS-stimulated macrophages, with an IC50 of 6.4 μM. This compound disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway. Additionally, NF-κB-IN-14 has demonstrated efficacy in reducing ear edema and inflammation in a mouse model of atopic dermatitis, highlighting its potential utility in inflammatory research. -
MyD88 Inhibitor
LM9 is a selective inhibitor of MyD88, a key adaptor protein in the Toll-like receptor (TLR) signaling pathway. By blocking the binding of TLR4 to MyD88, LM9 disrupts MyD88 homodimer formation and subsequent activation of the NF-κB signaling pathway. This compound demonstrates significant anti-inflammatory effects, mitigating atherosclerosis and fibrosis in models of obesity-induced cardiomyopathy. LM9 is valuable for research focused on understanding the mechanisms of inflammation, fibrosis, and cardiovascular diseases. -
TLR4/JNK/NF-κB Inhibitor
TLR4-IN-2 is an inhibitor targeting TLR4, JNK, and NF-κB pathways. It demonstrates anti-inflammatory properties by reducing nitric oxide production in LPS-stimulated RAW264.7 cells, with an IC50 of 23.2 µM. By inhibiting TLR4 expression and diminishing JNK phosphorylation, TLR4-IN-2 effectively suppresses NF-κB activation and the transcription of inflammation-related genes, leading to lower levels of iNOS, COX-2, and various inflammatory mediators. This compound shows potential for investigating therapeutic strategies in inflammatory diseases such as rheumatoid arthritis and other inflammatory disorders. -
NF-κB Inhibitor
Ergolide is a selective NF-κB/p65 and NLRP3 inhibitor that effectively disrupts the NF-κB signaling pathway and inhibits the nuclear translocation of p65. By irreversibly binding to the NACHT domain of NLRP3, Ergolie suppresses inflammasome assembly, significantly reducing the production of inflammatory mediators such as NO and PGE2. This compound promotes apoptosis in cancer cells, induces autophagy, and generates reactive oxygen species (ROS). Ergolide also enhances the therapeutic efficacy of vincristine and has been shown to alleviate acute lung injury in models of sepsis and inflammation, contributing to research in metastatic uveal melanoma, neurodegenerative diseases, and acute lymphoblastic leukemia. -
BChE Inhibitor
Pteryxin is a potent butyrylcholinesterase (BChE) inhibitor (IC50 = 12.96 μg/mL) with additional multi-target mechanisms including inhibition of NF-κB, MAPK, NLRP3 inflammasome activation, and modulation of the Nrf2/ARE pathways. This compound demonstrates significant anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin is suitable for research applications related to inflammatory diseases, osteoporosis, diabetes, and neurodegenerative disorders such as Alzheimer's disease. -
PC Inhibitor
Anemoside A3-methyl 6-aminohexanoate is a potent pyruvate carboxylase (PC) inhibitor, exhibiting a Kd value of 10.1 μM against human PC. This compound influences cellular pathways through the PC/NF-κB/NLRP3 inflammasome axis, demonstrating significant efficacy in alleviating symptoms of DSS-induced colitis in murine models. Anemoside A3-methyl 6-aminohexanoate serves as a useful tool in colitis-related research and studies focusing on the modulation of inflammatory pathways. -
NLRP3 Inhibitor
Yadanzigan is a potent NLRP3 inhibitor that exerts its anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing Reactive Oxygen Species production. This compound has been shown to mitigate LPS-induced acute lung injury (ALI) in murine models, highlighting its potential for research in inflammation-related conditions. Its mechanism of action positions Yadanzigan as a valuable tool for studying NLRP3-related pathways and their roles in various pathological processes. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
NLRP3 Inhibitor
NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
NF-κB Inhibitor
1-Caffeoylquinic acid is a potent inhibitor of NF-κB, demonstrating a significant binding affinity to the RH domain of p105 with a Ki value of 0.007 μM. This compound exhibits notable anti-oxidative stress properties and serves as an inhibitor for the PD-1/PD-L1 pathway. Its biological activities make it valuable for research applications in inflammation, immunity, and cancer studies. -
CHI3L1 Inhibitor
K284-6111 is a potent inhibitor of CHI3L1, demonstrating high affinity and oral bioavailability. It effectively suppresses CHI3L1 expression and disrupts key signaling pathways, including ERK and NF-κB, leading to reduced nuclear translocation of p50 and p65 as well as decreased phosphorylation of IκB. K284-6111 shows promise in alleviating memory dysfunction associated with Alzheimer's disease by mitigating amyloidogenesis and neuroinflammation. Additionally, it exhibits therapeutic potential in reducing atopic-like skin inflammation and protecting against LPS-induced liver injury. This compound is suitable for research into neurodegenerative diseases and inflammatory conditions. -
NF-κB Inhibitor
Valencene is a sesquiterpene that functions as an NF-κB inhibitor. It exhibits significant anti-inflammatory, antiallergic, and antioxidant activities by inhibiting the expression of Th2 chemokines and proinflammatory cytokines. In LPS-stimulated RAW 264.7 cells, Valencene effectively reduces the production of IL-1β and IL-6. Additionally, Valencene has demonstrated potential in alleviating symptoms of atopic dermatitis and restoring filaggrin expression in a DNCB-sensitized mouse model. -
NF-κB Inhibitor
Dimethyl diacetyl cystinate (DACDM) is a potent NF-κB inhibitor that modulates inflammation by shifting the intracellular redox balance towards an oxidized state. This compound increases the levels of oxidized glutathione (GSSG) and competes with activated NF-κB for binding sites on DNA, thus inhibiting the production of pro-inflammatory cytokines such as IL-1κ. DACDM is a valuable reagent for studies related to UVB-induced skin inflammation and various oxidative stress-related diseases. -
Akr1B1 Inhibitor
β-Glucogallin is a selective inhibitor of aldose reductase (AKR1B1), exhibiting an IC50 value of 58 μM with glyceraldehyde as the substrate. This compound displays significant antioxidant properties, reducing reactive oxygen species (ROS) and influencing key pathways involving PDGF, RAGE, and NF-κB. Additionally, β-Glucogallin enhances superoxide dismutase (SOD) activity and demonstrates hepatoprotective effects. Its biological activity makes it a valuable tool for research in retinal studies and related fields. -
HIPK2 Inhibitor
XRF-1021 is an orally active inhibitor of Homer-interacting protein kinase 2 (HIPK2), with an IC50 value of 0.18 μM. It effectively decreases the expression of fibrotic markers such as Fibronectin, Collagen I, and α-SMA in TGF-β1 stimulated renal cell lines, including NRK-49F and HK-2. XRF-1021 further inhibits key signaling pathways including TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch. This compound demonstrates potential in reducing renal injury and fibrosis in vivo, making it a valuable tool for research on chronic kidney disease. -
Toll-like Receptor (TLR) Inhibitor
Okanin is a potent Toll-like Receptor (TLR) inhibitor derived from the flowering plant Coreopsis tinctoria. It exhibits significant biological activity by attenuating lipopolysaccharide (LPS)-induced microglial activation via the inhibition of the TLR4/NF-κB signaling pathway. This compound is useful for research applications focusing on neuroinflammation and the modulation of immune responses in microglial cells. -
GPR75 Inhibitor
(Rac)-AAA is a potent inhibitor of GPR75, targeting the receptor to modulate key signaling pathways. This compound effectively blocks the downregulation of GPR75 expression induced by 20-HETE, leading to the inhibition of downstream pathways such as EGFR, AKT, NF-κB, and FAK. (Rac)-AAA also reverses 20-HETE-mediated epithelial-mesenchymal transition, characterized by the downregulation of vimentin and upregulation of E-Cadherin, while reducing MMP-2 activity and cancer cell migration. Additionally, it mitigates the upregulation of HIC-5 and affects the localization of PKC-α and phosphorylated AKT, making (Rac)-AAA a significant tool in the study of castration-resistant prostate cancer. -
RPTPβ/ζ Inhibitor
MY10 is a potent inhibitor of receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ) that exhibits oral bioactivity. It has been shown to reduce NF-κB p65 expression and activate c-Met tyrosine phosphorylation. Additionally, MY10 prevents the alcohol-induced downregulation of Ptprz1 and Alk expression, while attenuating binge-like ethanol consumption and associated rewards. This compound is valuable for investigating neurological and vascular diseases. -
IKKε Inhibitor
IKKε-IN-1 is a selective inhibitor of IKKε, a key enzyme involved in the NF-κB signaling pathway. This compound effectively reduces cell viability, inhibits colony formation, and diminishes cell migration in various cancer cell lines. Additionally, IKKε-IN-1 induces autophagy, illustrating its potential as a research tool in the study of multiple cancer types, including colorectal, hepatocellular, bladder, breast, lung, and cervical cancers. -
Carnitine Palmitoyltransferase I Upregulator, Peroxisome Proliferator-Activated Receptor α Upregulator, Nuclear Factor Erythroid 2-Related Factor 2 Activator, Nuclear Factor-Kappa B Inhibitor, Nuclear Factor Kappa B Kinase Subunit Beta Inhibitor, Sterol Regulatory Element-Binding Protein 1 Downregulator, Acetyl-CoA Carboxylase Downregulator, Acyl-CoA:Cholesterol Acyl Transferase 1 Inhibitor, Acyl-CoA:Cholesterol Acyl Transferase 2 Inhibitor
Esculeogenin A is a potent upregulator of Carnitine Palmitoyltransferase I and Peroxisome Proliferator-Activated Receptor α, while also acting as an activator of Nuclear Factor Erythroid 2-Related Factor 2. This compound exhibits key biological activities, including hepatoprotective, hypolipidemic, and antioxidant effects. Esculeogenin A modulates essential molecular targets such as SREBP1, NF-κB, and ACAT1/ACAT2, leading to enhanced hepatic fatty acid oxidation and diminished inflammation. It is applicable in research focused on nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia, showcasing its potential to improve liver function and mitigate the risk of associated metabolic disorders. -
COX-2 Inhibitor/PPAR-γ Activator
Zaltoprofen sulfoxide is a selective COX-2 inhibitor with an IC50 of 45.38 nM, as well as a PPAR-γ activator. This compound effectively inhibits NF-κB and MAPK inflammatory signaling pathways, making it a valuable tool in the study of inflammation and acute lung injury models. It is particularly relevant for research focused on LPS-induced acute lung injury. -
TrxR1 Inhibitor
Aurothioglucose is a potent inhibitor of thioredoxin reductase 1 (TrxR1), exhibiting an IC50 value of 65 nM. This compound effectively inhibits the DNA binding activity of NF-κB in vitro, highlighting its role in modulating key transcriptional pathways. Additionally, Aurothioglucose demonstrates anti-HIV and anti-rheumatic properties, making it a valuable reagent for research in infectious diseases and autoimmune disorders. -
ROS Inhibitor
Isodeoxyelephantopin is a sesquiterpene lactone with a primary mechanism as a reactive oxygen species (ROS) inhibitor. It demonstrates significant biological activity by inducing ROS generation and suppressing NF-κB activation, thereby contributing to its anticancer properties. Additionally, Isodeoxyelephantopin modulates long non-coding RNA (LncRNA) expression, making it a valuable reagent for breast cancer research and related fields. -
IKKβ Inhibitor
IKKβ-IN-7 is a selective inhibitor of IKKβ, exhibiting an IC50 value of 9.44 μM. This compound induces DNA damage, S-phase cell cycle arrest, and apoptosis, while also promoting reactive oxygen species accumulation and loss of mitochondrial membrane potential. By inhibiting the phosphorylation of p65 and IκBα, IKKβ-IN-7 effectively restricts p65 nuclear translocation and modulates NF-κB-regulated gene expression. This agent demonstrates significant antitumor activity in xenograft models, particularly in colorectal cancer, while exhibiting low cytotoxicity in normal cells. IKKβ-IN-7 serves as a valuable tool for research in the field of colorectal cancer. -
LUBAC Inhibitor
HOIPIN-8 is a highly potent inhibitor of the linear ubiquitin chain assembly complex (LUBAC), exhibiting an IC50 value of 11 nM. As a derivative of HOIPIN-1, it offers significantly enhanced inhibition, demonstrating a 255-fold increase in potency for petit-LUBAC, along with 10-fold and 4-fold increases in inhibiting LUBAC and TNF-α-mediated NF-κB activation, respectively. HOIPIN-8 serves as an essential research tool for investigating the cellular functions of LUBAC and its role in various biological processes. -
NF-κB/PON1 Pathway Inhibitor
NF-κB/PON1-IN-1 is an NF-κB/PON1 pathway inhibitor that exhibits pronounced antioxidant properties with an IC50 of 45.76 µM. This compound demonstrates hepatoprotective activity, making it valuable for research focused on inflammation and oxidative stress. Its mechanism of action positions it as a potential therapeutic tool in studies investigating liver-related diseases and cellular protection. -
RANKL Inhibitor
RANKL-IN-2 is a selective inhibitor of RANKL, exhibiting Kd values of 3.21 μM and 4.625 μM in surface plasmon resonance and microscale thermophoresis assays, respectively. By binding to RANKL, it disrupts the RANKL-RANK interaction, thereby suppressing osteoclastogenesis through the inhibition of reactive oxygen species, MAPK, and NF-κB signaling pathways. RANKL-IN-2 demonstrates efficacy in preventing RANKL-induced osteoclast formation, bone resorption, and the expression of osteoclast-specific genes and proteins in vitro. Additionally, RANKL-IN-2 has shown potential in preventing bone loss in ovariectomized mouse models, making it a valuable tool for osteoporosis research. -
Na+/K+-ATPase Inhibitor
(-)-γ-Cuparenol is a sesquiterpene compound that acts as an inhibitor of Na+/K+-ATPase, with an IC50 value of 23.6 μg/mL in porcine models. It has demonstrated the ability to reduce phytohemagglutinin (PHA)-induced activation of NF-AT and NF-κB in Jurkat cells, indicating potential applications in immunoregulation. Additionally, (-)-γ-Cuparenol exhibits antibacterial activity against certain Gram-positive and some Gram-negative bacteria, as well as weak inhibitory effects on Candida albicans. This compound is relevant for research exploring cardiovascular diseases and bacterial infections. -
Bacterial Inhibitor/Anti-inflammatory Agent
Cyclo(L-Pro-L-Val) is a peptide-based compound that functions as a bacterial inhibitor and anti-inflammatory agent. It exhibits antimicrobial activity against plant pathogens, such as R. fascians, and demonstrates significant inhibition of critical signaling molecules like IKKα, IKKβ, NF-κB, iNOS, and COX-2, contributing to its anti-inflammatory properties. This compound is valuable for research applications in developing biopesticides and investigating inflammation-related diseases. -
TrxR1 Inhibitor
Evernic Acid is a potent inhibitor of thioredoxin reductase 1 (TrxR1), demonstrating significant antiproliferative effects on human breast cancer cells. It disrupts the NF-κB signaling pathway by preventing p65 nuclear translocation and IκBα phosphorylation, which subsequently reduces inflammatory mediators. In addition to its role as an antioxidant and neuroprotective agent, Evernic Acid protects neurons from oxidative stress and mitochondrial dysfunction. Furthermore, it inhibits key enoyl reductases in Plasmodium falciparum and downregulates quorum sensing and biofilm formation in Pseudomonas aeruginosa, showcasing its antibacterial and antifungal properties. This compound is valuable for research focused on breast cancer, neurodegenerative diseases, and microbial infections. -
PDE4 Inhibitor
Glaucine, a selective phosphodiesterase 4 (PDE4) inhibitor, is an alkaloid sourced from Glaucium flavum. It demonstrates significant biological activities such as bronchodilation, anti-inflammatory effects, and anticancer properties. With a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes, Glaucine promotes relaxation of isolated human bronchi through calcium channel antagonism. Furthermore, it inhibits NF-κB activation, which downregulates MMP-9 expression, thereby impairing the migration and invasion of breast cancer cells. Glaucine is relevant for research applications in asthma and breast cancer. -
PDE4 Inhibitor
LT-104A is a selective phosphodiesterase 4 (PDE4) inhibitor that effectively elevates intracellular cyclic AMP (cAMP) levels, exhibiting an EC50 of 1.9 μM and inhibiting PDE4D3 activity with an IC50 of 9.3 μM. By activating the cAMP-PKA-CREB anti-inflammatory signaling pathway, LT-104A suppresses expression of NF-κB-related genes such as Il1b and Nos2. This compound is valuable for research focused on inflammation-related diseases and therapeutic interventions aimed at modulating inflammatory responses. -
PI3K/Akt Inhibitor, MAPK Inhibitor, NF-κB Inhibitor, Nrf2/ARE Activator
JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms. -
p38 MAPK Inhibitor
Ganoderterpene A is a potent inhibitor of p38 MAPK, demonstrating significant anti-inflammatory and anti-apoptotic activity. It effectively attenuates LPS-induced inflammation and apoptosis by suppressing the MAPK and TLR-4/NF-κB signaling pathways in BV-2 cells. This compound is valuable for research applications focused on neuroinflammation and cellular stress responses.
